Two-Year Results of Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal Vasculopathy; A Real Life Experience

Sibel Ahmet, Okkes Baz, Gokhan Demir, Ali Demircan, Zeynep Alkin, Abdullah Ozkaya, Alperen Koc, Muhittin Taskapili
University of Health Sciences, Beyoglu Eye Training and Research Hospital, Istanbul, Turkey

Abstract

Objectives: The aim of this study was to evaluate the 2-year outcomes of intravitreal ranibizumab (IVR) therapy in combination with photodynamic therapy (PDT) in patients with polypoidal choroidal vasculopathy (PCV).

Methods: Patients with PCV who presented at the clinic between January 2013 and January 2014 were reviewed retrospectively. Twenty-three eyes of 23 patients were included in this study. Indocyanine green angiography was performed to confirm the diagnosis of PCV in all patients. IVR was administered within a week following PDT, then followed by additional IVR as needed. Best corrected visual acuity (BCVA) measurement, biomicroscopic examination, and central macular thickness (CMT) measurement via optical coherence tomography at baseline and at 3, 6, 12, 18, and 24 months were performed. The mean change in BCVA and CMT at follow-up was compared with the baseline.

Results: A total of 23 eyes of 23 patients were included in this study. The mean age of the patients was 65.8±7.4 years (range: 55-82 years). The mean BCVA (logMAR, or logarithm of the minimum angle of resolution) was 0.68±0.45 at baseline, 0.66±0.45 at 3 months (p=0.43), 0.69±0.43 at 6 months (p=0.95), 0.69±0.42 at 12 months (p=0.54), and 0.70±0.42 at 24 months (p=0.56). The mean CMT was 334.5±99.4 μm at baseline, 313.4±96.1 μm at 3 months (p=0.27), 319.1±106.5 μm at 6 months (p=0.44), 303.52±128.33 μm (p=0.17) at 12 months, 246.6±80.8μm at 18 months (p=0.0001), and 226.9±71.7 μm at 24 months (p=0.0001).

Conclusion: Verteporfin PDT administered in combination with IVR was an effective treatment for preserving VA in PCV for a 2-year period. Our results need to be confirmed in further studies in a real-life setting.

Keywords: Combined therapy, polypoidal choroidal vasculopathy, ranibizumab.

Introduction

Polypoidal choroidal vasculopathy (PCV) is characterized by a complex of branching vascular networks terminating in aneurysmal or polypoidal lesions (1, 2). Indocyanine green angiography (ICGA) is the optimal method to detect PCV, which is similar to an occult choroidal neovascular membrane in fundus fluorescein angiography, in the demonstration of vascular network structures and polyps (3, 4).

Recently, many studies have had successful results in the treatment of subfoveal PCV using photodynamic therapy (PDT), anti-vascular endothelial growth factor (anti-VEGF) agents, or a combination therapy with PDT and anti-VEGF agents (5). Though PDT is effective in illustrating branched...
network vaso-occlusion and polyps, it can be harmful to the physiological choriocapillary layer beyond the irradiated area, and repeated sessions of PDT result in persistent choriocapillary nonperfusion. The rationale for anti-VEGF treatment in PCV is based on the demonstration of VEGF expression in the aqueous humor of patients with PCV. Intravitreally injected anti-VEGF agents reduce the exudation and leakage from the vascular network and polyps. However, it has been demonstrated that the effect of anti-VEGF treatment alone on the regression of polyps was limited. Hence, combination therapy can exert synergistic effects on regressing polyps and better maintain visual acuity (VA) and retinal morphology when compared with PDT or anti-VEGF monotherapy (6).

The aim of this study was to evaluate the 2-year outcomes of intravitreal ranibizumab (IVR) therapy in combination with PDT in patients with PCV.

Methods

Patients with PCV who presented at the clinic between January 2013 and January 2014 were reviewed retrospectively. ICGA was performed to confirm the diagnosis in each patient. Symptomatic patients with subretinal reddish-orange spheroidal lesions on funduscopic examination, leakage on optical coherence tomography (OCT), and characteristic aneurysmal polypoidal lesions with a branching network of choroidal vessels seen on ICGA were included in the study. Patients were excluded if they had any of the following: previous treatment for PCV or intraocular surgery within the previous 30 days, verteporfin or fluorescein contraindication, pathological myopia, vascular diseases of the retina, diseases of the retinal pigment epithelium, or choroid disease other than PCV.

Patient consent was obtained to perform PDT and anti-VEGF therapy after informing them about their current condition, the natural course, and treatment success rate and risks, in accordance with the principles of the Declaration of Helsinki. IVR was administered within 1 week after PDT, and followed by additional IVR as needed.

For PDT, 6 mg/m² verteporfin (Visudyne; Novartis AG, Basel, Switzerland) was administered intravenously at a rate of 3 mL/minute in the form of 30 mL of solution in 5% dextrose. The laser was applied at a wavelength of 689 nm with a power of 600 mW/cm² for 83 seconds, 15 minutes after the initiation of the infusion. The largest linear diameter of polyps and abnormal, dilated choroidal vascular networks was measured using ICGA. The spot size of the laser beam was calculated by adding 100μ to the largest linear diameter of the lesion to be treated.

All injections were administered under sterile conditions and under topical anesthesia. Sterilization of the eye lids and eyelashes was achieved with 5% povidone iodine.

Ranibizumab (0.5mg/0.05mL) was injected intravitreally with a 27-G needle from 3 to 4 mm distance to the limbus. The use of 0.5% moxifloxacin was recommended 5 times daily for 1 week after the injection.

Intravitreal administration of ranibizumab was considered when intraretinal/subretinal fluid observed on OCT was related to polypoidal lesions or a patient had decreased VA.

Thereafter, patients were followed in accordance with the retreatment criteria for IVR according to the parameters recommended in the PRONTO study: evidence of persistent fluid on OCT at least 1 month after the previous injection, an increase in OCT central macular thickness (CMT) ≥100 μm, a new macular hemorrhage, or a decrease in best corrected visual acuity (BCVA) >5 letters (7). Retreatment with PDT was performed when ICGA showed active polypoidal lesions persisted 3 months after the previous PDT treatment.

Initially, a full ophthalmic examination, including measurement of BCVA with a Snellen chart, anterior and posterior segment examination with slit-lamp biomicroscopy, color fundus photography, fluorescein angiography (HRA-2; Heidelberg Engineering, Heidelberg, Germany), and OCT imaging (Spectralis; Heidelberg Engineering, Heidelberg, Germany) were performed. The demographic details of the patients, the duration of the follow-up period, the number of IVR injections and PDT sessions, and BCVA and CMT at baseline and at 3, 6, 12, 18, and 24 months were recorded. A paired-sample t-test was used for statistical analysis. Significance was assessed at p<0.05.

Results

Twenty-three eyes of 23 patients (11 right, 12 left) were included in this study. The mean age of the patients was 65.8±7.4 years (range: 55-82 years). Table 1 is a summary of the demographic data of the patients.

The mean BCVA (logMAR, or logarithm of the minimum visual angle) of the conjunctival sac was achieved with 5% povidone iodine.

<table>
<thead>
<tr>
<th>Table 1. Baseline characteristics of patients with PCV</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
</tr>
<tr>
<td><strong>Range</strong></td>
</tr>
<tr>
<td><strong>Gender</strong></td>
</tr>
<tr>
<td><strong>Male (%)</strong></td>
</tr>
<tr>
<td><strong>Female (%)</strong></td>
</tr>
<tr>
<td><strong>BCVA at baseline (logMAR)</strong></td>
</tr>
<tr>
<td><strong>CMT at baseline (μ)</strong></td>
</tr>
</tbody>
</table>

BCVA: best corrected visual acuity; CMT: central macular thickness; PCV: polypoidal choroidal vasculopathy.
Ahmet et al., Polypoidal Choroidal Vasculopathy, Anti-VEGF

Mean logMAR BCVA

**Figure 1.** The change in mean logMAR best corrected visual acuity over time.

BCVA: best corrected visual acuity.

The mean CMT was 334.5±99.4 μm at baseline, 313.4±96.1 μm at 3 months (p=0.27), 319.1±106.5 μm at 6 months (p=0.44), 303.52±128.33 μm (p=0.17) at 12 months, 246.6±80.8 μm at 18 months (p=0.0001), and 226.9±71.7 μm at 24 months (p=0.0001). Compared with the baseline, no statistically significant difference was found at 3, 6, and 12 months. However, a statistically significant decrease was observed at 18 and 24 months. The changes in mean CMT are provided in Figure 2.

The pretreatment and posttreatment ICGA and OCT findings can be seen in Figure 3.

During the 24-month follow-up period, the mean number of PDT sessions was 1.5±0.5 (range: 1-3) and the mean angle of resolution) was 0.68±0.45 at baseline, 0.67±0.45 at 3 months (p=0.24), 0.66±0.45 at 6 months (p=0.43), 0.69±0.43 at 12 months (p=0.95), 0.69±0.42 at 18 months (p=0.54), and 0.70±0.42 at 24 months (p=0.56). Compared with the baseline measurements, no statistically significant difference was found during follow-up. Figure 1 illustrates the changes in mean logMAR BCVA.

**Figure 2.** The change in mean central macular thickness observed with optical coherence tomography over time.

The mean CMT was 334.5±99.4 μm at baseline, 313.4±96.1 μm at 3 months (p=0.27), 319.1±106.5 μm at 6 months (p=0.44), 303.52±128.33 μm (p=0.17) at 12 months, 246.6±80.8 μm at 18 months (p=0.0001), and 226.9±71.7 μm at 24 months (p=0.0001). Compared with the baseline, no statistically significant difference was found at 3, 6, and 12 months. However, a statistically significant decrease was observed at 18 and 24 months. The changes in mean CMT are provided in Figure 2.

The pretreatment and posttreatment ICGA and OCT findings can be seen in Figure 3.

During the 24-month follow-up period, the mean number of PDT sessions was 1.5±0.5 (range: 1-3) and the mean
Ahmet et al., Polypoidal Choroidal Vasculopathy, Anti-VEGF

Number of IVR applications was 5.3±1.06 (range: 3-7). At the end of 24 months, 14 patients (60.9%) were referred to follow-up without any treatment, 8 patients (34.8%) were scheduled for reinjection of IVR, and re-PDT was recommended for 1 patient (4.3%). A subretinal hemorrhage occurred in 4 patients (17.2%).

Discussion

Little is known about the pathogenesis of PCV. It remains unclear whether PCV represents abnormal vessels from the choroidal circulation or is a variant of choroidal neovascularisation (1). It is well known, however, that PCV primarily involves the inner choroidal vasculature that is well differentiated from the middle and larger choroid vessels. PDT and anti-VEGF agents are the current treatment modalities for PCV. PDT induces regression or resolution of polyps via its angio-occlusive mechanism of action. PDT appears to be safe and effective in patients with active and symptomatic subfoveal PCV lesions. Increased VEGF levels have been observed in PCV patients (23). Therefore, anti-VEGF therapy might theoretically be beneficial in PCV treatment. Recent studies have reported that intravitreal anti-VEGF injections help to stabilize VA and reduce serous retinal detachment in the short term. However, intravitreal injections of anti-VEGF as a monotherapy have limitations in preventing the aggravation of polypoidal lesions (11); thus, a combination of anti-VEGF injection and PDT has been attempted as an alternative treatment.

PDT is an established treatment modality for PCV (8). The mechanism of action involves a vaso-occlusive effect. When PDT activates the photosensitizer verteporfin at the site of the laser application, it induces vascular thrombosis, reduced perfusion, and PCV regression (9, 10). A high polyp regression rate of 82% to 95% with PDT monotherapy has been reported (9, 14, 15).

It has been demonstrated in many studies that PDT alone had a success rate of 80% to 95% in the treatment of subfoveal PCV (11). Gomi et al. (12) reported that BCVA in 84% of patients remained stable or increased after PDT, and 85% of polyps had regressed at 1 year. In a study that was presented as the result of 1 year of follow-up in patients who had undergone PDT, Senturk et al. (13) found that 60% of the cases had increased VA and 40% had stabilized. Otani et al. (14) demonstrated in a prospective study of 45 eyes treated with PDT that 82.2% of the polypoidal lesions had regressed at the end of 1 year. Furthermore, Muslubas et al. (16) showed that BCVA in 89% of PDT patients remained stable or increased, and 67% of polyps had regressed at 24 months.

Several studies have determined that intravitreal anti-VEGF combined with PDT in PCV patients is more effective than single anti-VEGF therapy in increasing VA, and
preventing subretinal hemorrhage and polyp recurrence (20, 21, 22). A combined PDT and intravitreal anti-VEGF injection was reported to increase BCVA and to decrease foveal thickness in a 12-month follow-up (17).

Ruamviboonsuk et al. (14) reported that 58.3% of patients had a BCVA gain of 15 letters or more, and the polyps in all patients regressed without recurrence with combined therapy. In the study performed by Muslubas et al., 88% of the patients who underwent combined treatment had a significant improvement in BCVA. However, a statistically significant decrease in CMT was observed (16). The EVEREST trial was the first randomized, controlled trial investigating whether PDT, either as a monotherapy or in combination with IVR, was more efficacious than ranibizumab monotherapy in achieving complete polyp regression as assessed by ICGA. In this study, there was no difference between PDT alone and combined anti-VEGF treatment in terms of BCVA gain. The rate of complete regression in polyps was found to be 77.8% with combined treatment, 71.4% with PDT monotherapy, and 28.6% with ranibizumab monotherapy (6, 19).

A mean of 5 injections were performed in the present study. In a study conducted by Marcus et al. (24), a mean of 7.2 injections per eye was administered over a 24-month follow-up period. They observed a 1.2 Snellen letter-increase at month 24 compared with the baseline. In contrast, we observed no change in BCVA compared to the initial measurement at 24 months. It can be speculated that this was probably due to the smaller number of injections.

The current study has some limitations. First, this was a retrospective study. Additionally, this study had a small sample size and was without a control group.

In conclusion, our findings suggested that combined PDT and IVR was effective in preserving VA and retinal morphology in the long-term. To establish the sustained beneficial effects of combination therapy, further investigation with controlled studies is needed.

Disclosures

Financial Disclosure: This retrospective study was not supported by any company. None of the authors has financial or proprietary interests in any material or method mentioned. These data have not been previously published.

Peer-review: Externally peer-reviewed.

Conflict of Interest: None declared.

Authorship Contributions: Involved in design and conduct of the study (ZA, AO, SA, OB); preparation and review of the study (ZA, AO, AD, GD, MT); data collection (ZA, AO, SA, OB, GD); and statistical analysis (ZA, AK, AD, GD).

References


